



JFW

Attorney Docket No. UNI.26

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANT: JIA }
SERIAL NO.: 10/817,330 }
FILED: APRIL 02, 2004 }
TITLE: FORMULATION OF DUAL
CYCLOXYGENASE (COX) AND
LIPOXYGENASE (LOX) INHIBITORS
FOR MAMMAL SKIN CARE }

EXAMINER:
ART UNIT: 1614
CONFIRMATION NO.: 1136

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

2nd INFORMATION DISCLOSURE STATEMENT

Applicant calls the Examiner's attention to the patents and publications listed on the attached Form PTO-1449, copies of required documents enclosed, which may be material to examination of the above identified application.

TIME OF TRANSMITTAL

This Information Disclosure Statement is being filed under 37 CFR § 1.97(b). This Statement is filed within at least one of the following time periods:

- (a) within three months of the filing date of a national application (other than a CPA under 37 CFR § 1.53(d));
- (b) within three months of the date of entry of the national stage as set forth in 37 CFR § 1.491 in an international application;
- (c) before the mailing of a first Office Action on the merits; or
- (d) before the mailing of a first Office Action after the filing of a request for continued examination under 37 CFR § 1.114.

No fee is believed to be due in this instance. However, the undersigned hereby authorizes the charging of any fees created by the filing of this document to Deposit Account No. 19-5117.

**37 CFR 1.8
CERTIFICATE OF MAILING**


I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on Sept. 17, 2004.

Signature: Denise S. Magee
Name: Denise S. Magee

The filing of this Information Disclosure Statement shall not be construed as an admission against interest in any manner. This listed patents and publications are believed of interest herein and consideration and citation of as interest by Examiner is respectfully requested.

Respectfully submitted,

Date: September 17, 2004


Rosemary P. Kellogg, #39,726
Swanson & Bratschun, L.L.C.
1745 Shea Center Drive, Suite 330
Highlands Ranch, Colorado 80129
303-268-0066 Telephone
303-268-0065 Facsimile

cc: Qi Jia

S:\CLIENTFOLDERS\UNIGEN PHARMACEUTICALS\UNI26\UTILITY\IDS #2.DOC



| | | | |
|---|--|----------------------------|--------------------------|
| DRM PTO-1449 List of Information Cited by Applicant Page 1 of 1 | U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE | ATTY. DOCKET NO. UNI.26 | SERIAL NO. 10/817,330 |
| | APPLICANT JIA | | |
| | FILING DATE April 02, 2004 | GROUP 1136 | |

| U.S. PATENT DOCUMENTS | | | | | | | |
|-----------------------|----|--------------------|------------|----------------|-----|-------------|--------------|
| EXAM. INITIAL | | DOCUMENT NUMBER | DATE | NAME | CLS | SUB- CLS | FILE DATE |
| | AA | 5,773,014 | 06/30/1998 | PERRIER ET AL. | | | |
| | AB | 6,391,872 | 05/21/2002 | MARFAT | | | |
| | AC | | | | | | |
| | AD | | | | | | |
| | AE | | | | | | |
| | AF | | | | | | |
| | AG | | | | | | |
| | AH | | | | | | |
| | AI | | | | | | |
| | AJ | | | | | | |
| | AK | | | | | | |
| | AL | | | | | | |
| | AM | | | | | | |
| | AN | | | | | | |
| | AO | | | | | | |
| | AP | | | | | | |
| | AQ | | | | | | |

| FOREIGN PATENT DOCUMENTS | | | | | | |
|--------------------------|----|--------------------|------------|---------|-----|------------|
| EXAM. INITIAL | | DOCUMENT NUMBER | DATE | COUNTRY | CLS | SUB CLS |
| | AR | EP 1 147 764 A2 | 10/24/2001 | EUROPE | | |
| | AS | | | | | |
| | AT | | | | | |
| | AU | | | | | |
| | AV | | | | | |
| | AW | | | | | |
| | AX | | | | | |

| OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.) | |
|--|-----|
| | AY |
| | AZ |
| | AAA |
| | AAB |
| | AAC |
| | AAD |

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.